Skip to main content

Galapagos Genomics to Provide Proctor & Gamble with Drug Targets

NEW YORK, June 11 - Galapagos Genomics has signed on to provide Procter & Gamble Pharmaceuticals with protein drug targets related to osteoporosis, the Mechelen, Belgium, company said today.


Under the agreement, Galapagos will provide Proctor & Gamble with protein targets that impact bone formation. Proctor & Gamble will validate the targets and may initiate development of osteoporosis drug candidates based on these targets.


Galapagos is to receive option fees, milestone payments, and royalties on sales of any products developed from these targets, the company said, but did not disclose further financial terms of the deal.


Galapagos has discovered these targets using PhenoSelect, its gene expression platform which uses arrayed adenoviruses containing human genes to identify and validate targets.


This agreement expands on a a previous deal in which Proctor & Gamble agreed to use PhenoSelect to discover targets internally.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.